Erlotinib

Active ingredient: Erlotinib Hydrochloride

In short: Erlotinib tablets are indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenanc

Forms & strengthsErlotinib Tablets equivalent to 25 mg of erlotinib are white to off-white, round, film-coated tablets, debossed with '913' on one side and plain on other side. …
LabelZydus Pharmaceuticals USA Inc.
Label updatedOct 11, 2023

What is Erlotinib used for?

Erlotinib tablets are indicated for:

The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen .

Limitations of use:

Safety and efficacy of erlotinib tablets have not been established in patients with NSCLC whose tumors have other EGFR mutations .

Erlotinib tablets are not recommended for use in combination with platinum-based chemotherapy .

Erlotinib tablets in combination with gemcitabine are indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer .

Erlotinib dosage

Select patients for the treatment of metastatic NSCLC with erlotinib based on the presence of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations in tumor or plasma specimens . If these mutations are not detected in a plasma specimen, test tumor tissue if available. Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics.

The recommended daily dose of erlotinib for NSCLC is 150 mg taken on an empty stomach, i.e., at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.

The recommended daily dose of erlotinib for pancreatic cancer is 100 mg taken once daily in combination with gemcitabine. Take erlotinib on an empty stomach, i.e., at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs .

† For additional information see Warnings and Precautions (5) .

* Reduce erlotinib by 50 mg decrements when restarting therapy following withholding treatment for a dose-limiting toxicity that has resolved to baseline or grade ≤ 1.

‡ For additional information see Drug Interactions (7) .

§ For additional information see Clinical Pharmacology (12.3) .

Adverse Reactions

Pulmonary† | Interstitial Lung Disease (ILD) | Discontinue erlotinib

During diagnostic evaluation for possible ILD | Withhold erlotinib*

Hepatic† | Severe hepatic toxicity that does not improve significantly or resolve within three weeks | Discontinue erlotinib

In patients with pre-existing hepatic impairment or biliary obstruction for doubling of bilirubin or tripling of transaminases values over baseline | Withhold erlotinib* and consider discontinuation

In patients without pre-existing hepatic impairment for total bilirubin levels greater than 3 times the upper limit of normal or transaminases greater than 5 times the upper limit of normal | Withhold erlotinib* and consider discontinuation

Renal† | For severe (CTCAE grade 3 to 4) renal toxicity | Withhold erlotinib* and consider discontinuation

Gastrointestinal† | Gastrointestinal perforation | Discontinue erlotinib

For persistent severe diarrhea not responsive to medical management (e.g., loperamide) | Withhold erlotinib*

Skin† | Severe bullous, blistering or exfoliating skin conditions | Discontinue erlotinib*

For severe rash not responsive to medical management | Withhold erlotinib

Ocular† | Corneal perforation or severe ulceration | Discontinue erlotinib

For keratitis of (NCI-CTC version 4.0) grade 3 to 4 or for grade 2 lasting more than 2 weeks | Withhold erlotinib*

For acute/worsening ocular disorders such as eye pain | Withhold erlotinib* and consider …

How to take Erlotinib — instructions & advice from the label

S

k

in rash, bullous and exfoliative skin disorders

Advise patients that skin reactions can occur or worsen on sun-exposed areas while taking erlotinib, and proactive intervention may include alcohol-free emollient cream and use of sunscreen or avoidance of sun exposure. Advise patients that hyperpigmentation or dry skin, with or without digital skin fissures, have been reported and in the majority of cases were associated with rash .

Advise patients that erlotinib can increase the risk of bullous and exfoliative skin disorders and to seek immediately medical attention for severe skin reactions .

Diarrhea

Advise patients that diarrhea can usually be managed with loperamide and to contact their healthcare provider for severe or persistent diarrhea .

Interstitial lung disease

Advise patients of the risk of severe or fatal ILD, including pneumonitis. Advise patients to contact their healthcare provider immediately to report new of worsening unexplained shortness of breath or coughing .

Renal failure

Advise patients of the risk of developing renal failure. Inform patients of the need for the healthcare provider to monitor kidney function and electrolytes . …

Warnings & precautions

Do not take this medicine if: None.

Cases of serious ILD, including fatal cases, can occur with erlotinib treatment. The overall incidence of ILD in approximately 32,000 erlotinib-treated patients in uncontrolled studies and studies with concurrent chemotherapy was approximately 1.1%. In patients with ILD, the onset of symptoms was between 5 days to more than 9 months (median 39 days) after initiating erlotinib therapy.

Withhold erlotinib for acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, permanently discontinue erlotinib .

Hepatorenal syndrome, severe acute renal failure including fatal cases, and renal insufficiency can occur with erlotinib treatment. Renal failure may arise from exacerbation of underlying baseline hepatic impairment or severe dehydration. The pooled incidence of severe renal impairment in the 3 monotherapy lung cancer studies was 0.5% in the erlotinib arms and 0.8% in the control arms. The incidence of renal impairment in the pancreatic cancer study was 1.4% in the erlotinib plus gemcitabine arm and 0.4% in the control arm. Withhold erlotinib in patients developing severe renal impairment until renal toxicity is resolved. Perform periodic monitoring of renal function and serum electrolytes during erlotinib treatment .

Hepatic failure and hepatorenal syndrome, including fatal cases, can occur with erlotinib treatment in patients with normal hepatic function; the risk of hepatic toxicity is increased in patients with baseline hepatic impairment. In clinical studies where patients with moderate to severe hepatic impairment were excluded, the pooled incidence of hepatic failure in the 3 monotherapy lung cancer studies was 0.4% in the erlotinib arms and 0% in the control arms. …

Erlotinib side effects

The following serious adverse reactions, which may include fatalities, are discussed in greater detail in other sections of the labeling:

Interstitial Lung Disease (ILD)

Renal Failure

Hepatotoxicity with or without Hepatic Impairment

Gastrointestinal Perforation

Bullous and Exfoliative Skin Disorders

Cerebrovascular Accident

Microangiopathic Hemolytic Anemia with Thrombocytopenia

Ocular Disorders

Hemorrhage in Patients Taking Warfarin

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Safety evaluation of erlotinib is based on more than 1,200 cancer patients who received erlotinib as monotherapy, more than 300 patients who received erlotinib 100 mg or 150 mg plus gemcitabine, and 1,228 patients who received erlotinib concurrently with other chemotherapies. The most common adverse reactions with erlotinib are rash and diarrhea usually with onset during the first month of treatment. The incidences of rash and diarrhea from clinical studies of erlotinib for the treatment of NSCLC and pancreatic cancer were 70% for rash and 42% for diarrhea.

Non-Small Cell Lung Cancer

First-Line Treatment of Patients with EGFR Mutations

The most frequent (≥ 30%) adverse reactions in erlotinib-treated patients were diarrhea, asthenia, rash, cough, dyspnea, and decreased appetite. …

Drug interactions

CYP3A4 Inhibitors

Coadministration of erlotinib with a strong CYP3A4 inhibitor or a combined CYP3A4 and CYP1A2 inhibitor increased erlotinib exposure. Erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2. Increased erlotinib exposure may increase the risk of exposure-related toxicity .

Avoid coadministering erlotinib with strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) or a combined CYP3A4 and CYP1A2 inhibitor (e.g., ciprofloxacin). Reduce the erlotinib dosage when coadministering with a strong CYP3A4 inhibitor or a combined CYP3A4 and CYP1A2 inhibitor if coadministration is unavoidable .

CYP3A4 Inducers

Pre-treatment with a CYP3A4 inducer prior to erlotinib decreased erlotinib exposure . Increase the erlotinib dosage if coadministration with CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, rifabutin, rifapentine, phenobarbital and St. John's wort) is unavoidable .

CYP1A2 Inducers and Cigarette Smoking

Cigarette smoking decreased erlotinib exposure. …

About this medicine

Erlotinib tablet, a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy) -4-quinazolinamine hydrochloride. Erlotinib tablet contains erlotinib as the hydrochloride salt that has the following structural formula:

Erlotinib hydrochloride has the molecular formula C22H23N3O4•HCl and a molecular weight of 429.90. The molecule has a pKa of 5.35 at 25°C. Erlotinib hydrochloride is off white to pale yellow powder. It is slightly soluble in methanol and practically insoluble in acetonitrile and acetone.

Aqueous solubility of erlotinib hydrochloride at 25˚C is dependent on pH with increased solubility at a pH of less than 5 due to protonation of the secondary amine. Over the pH range of 1.2 to 9.5, maximal solubility of approximately 0.15 mg/mL occurs at a pH of approximately 2. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c35e019d-ec34-4e61-9400-a7ae7913e025. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate